# Tvardi Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tvardi-therapeutics

- Industry: Biotechnology
- Headquarters: Houston, US
- Website: www.tvarditherapeutics.com
- Total disclosed funding: $112M
- Latest round: Series B (Jun 3, 2021)
- Investors on record: 6

## About

Tvardi Therapeutics is focused on developing innovative oral small molecule therapies targeting STAT3 to address fibrosis-related diseases. The company aims to provide effective solutions for unmet medical needs within this therapeutic area.Tvardi Therapeutics, Inc. was founded in 2017 in Houston, US. The company specializes in the development of therapies for chronic fibrosis-driven diseases such as idiopathic pulmonary fibrosis (IPF). Led by CEO Imran Alibhai, Tvardi has completed 4 deals, with its most recent funding round being a Series B, raising USD 72.42 mn on June 3, 2021. Major investors include 683 Capital Management, ArrowMark Partners, Palkon Capital Management, and Slate Path Capital, contributing to a total fundraising of USD 72.42 mn and a current company valuation of USD 190.51 mn.Tvardi Therapeutics specializes in the development of innovative, oral small molecule therapies aimed at targeting STAT3 to address fibrosis-driven diseases with significant unmet medical needs. The company’s core product offerings focus on conditions like idiopathic pulmonary fibrosis (IPF), which currently lacks effective treatments. These therapies are intended for clinical settings, targeting healthcare providers, research institutions, and pharmaceutical partners in North America and Europe, with end users being patients diagnosed with IPF and other fibrosis-related diseases.Tvardi Therapeutics generates revenue through partnerships and collaborations with pharmaceutical companies and research institutions that aid in the development and commercialization of its therapies. Collaborative agreements allow partners to access Tvardi's proprietary products and technology, with specific pricing structures reflecting their value. The company’s flagship products, targeting significant healthcare challenges, are essential components of its revenue streams as they advance through clinical trials and into the market.Following the Series B funding round in June 2021, Tvardi Therapeutics, Inc. plans to use the raised USD 72.42 mn to advance its product candidates through multiple clinical data readouts in mid-stage trials for cancer and fibrosis. The company is also focused on expanding into North American and European markets, enhancing its presence among healthcare providers and research institutions. These strategic initiatives aim to significantly enhance the company's portfolio and market reach by targeting regions with high unmet medical needs.

## Funding rounds

- Series B, Jun 3, 2021, $72M — ArrowMark Partners, Slate Path Capital, Palkon Capital Management, 683 Capital Management, Sporos Bioventures
- Series B, May 1, 2020, $40M — Solas BioVentures

## Investors

- Solas BioVentures (https://capitalatlas.ai/funds/solas-bioventures) — Series B
- ArrowMark Partners — Series B
- Slate Path Capital — Series B
- Palkon Capital Management — Series B
- 683 Capital Management — Series B
- Sporos Bioventures (https://capitalatlas.ai/funds/sporos-bioventures) — Series B